Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

TrinidadEM.pdf (112.23 KB)

Document type

Article

Version

Published version

Publication date

2016-12-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/125355

RANKL inhibitors for osteosarcoma treatment: hope and caution

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.21037/atm.2016.12.10

Abstract

Chen and collaborators propose RANKL blockade for the treatment and prevention of aggressive RANKL-overexpressing osteosarcoma (OS) in humans. Here we comment the main findings, putative applications and concerns. OS is the most common primary bone cancer, which occurs primarily in children and adolescents, severely affecting survivors’ quality of life. Current treatment for newly diagnosed OS includes three main components: preoperative chemotherapy, surgical resection, and postoperative chemotherapy (1). This strategy has improved the outcome of patients with localized OS. However, patients with advanced, metastatic, and recurrent OSs continue to experience a quite poor prognosis. After aggressive treatment with both surgery and chemotherapy, the 5-year survival rate for OS patients with localized disease is about 65%, whereas it is less than 20% for patients with metastases. The use of adjuvant chemotherapy provides no survival advantage for patients with pulmonary metastases (2). So that, it is of particular importance to develop molecularly targeted therapy to treat patients with this metastatic bone malignancy, on the basis of in-depth understanding of signaling mechanisms involved in OS tumorigenesis.

Subject

Osteosarcoma, Quimioteràpia

Subject (English)

Chemotherapy

Citation

Collections

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

TRINIDAD ALVAREZ, Eva Maria and GONZÁLEZ SUÁREZ, Eva. RANKL inhibitors for osteosarcoma treatment: hope and caution. Annals of Translational Medicine. 2016. Vol. 4, num. 24. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/125355

Export metadata

JSON - METS

Share record